liquidia.com (LQDA): Price to Earnings Adjusted for Growth Rate

Symbol and logo of brand Liquidia Corporation (LQDA)

Liquidia Corporation (LQDA) ensures the stable delivery of inhalation agents to pharmacies while maintaining their chemical stability. The P/E ratio relative to earnings growth on this chart demonstrates the market valuation of the asset, where the value is fixed at 0.00. PRINT technologies automate the creation of microparticles, eliminating human error. The business is based in the US, which minimizes geopolitical risks and sanctions pressure.

LQDA - Liquidia Corp PEG Multiple over the range 07/04/2022 - 11/14/2026

Metric breakdowns and analytics for Liquidia Corporation (LQDA)

- share price and consensus valuation forecast:
Fundamental company analysis:Liquidia Corp LQDA
Mass-produced product of liquidia.com

This ratio assesses the balance of the asset's market value relative to profit expansion rates, where a value below one signals that the business is undervalued. By analyzing the P/E ratio against growth expectations, an investor can see the scaling efficiency of Liquidia Corporation (LQDA), whose advantage in microparticle synthesis automation via the PRINT system should convert into accelerated profits and reduced operational risks.

Competing companies

HLN (Haleon PLC) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Kenvue Corp KVUE|Verona Pharma Inc. (VRNA) - Price to Earnings Adjusted for Growth Rate|MENS: Price/Earnings to Growth Multiple|ligand.com - Company Value to Earnings Growth Ratio|AMRX: PEG Multiple|Perrigo Company PLC - Growth-Adjusted Payback Ratio|ALVO (Alvotech Corp) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Galapagos Corp GLPG|Price/Earnings to Growth Ratio ANI Pharmaceuticals (ANIP)|MNKD (mannkindcorp.com) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Amphastar Pharmaceuticals, Inc. AMPH|Pacira Pharmaceuticals - Price/Earnings to Growth Ratio|ARS Pharma - PEG Multiple|Growth-Adjusted Market Cap to Net Income Theravance Corp TBPH|Aquestive Therapeutics (AQST) - Price/Earnings to Growth Ratio|Price to Net Income Growth Ratio scPharmaceuticals SCPH|Price/Earnings to Growth Multiple TECX|PEG Multiple Tonix Pharma|PEG Multiple SXTC|Growth-Adjusted Market Cap to Net Income eupraxiapharma.com|PEG Multiple BHST (BioHarvest Sciences)|EXOZ: Growth-Adjusted P/E Ratio|Oramed Pharma - PEG Multiple|Growth-Adjusted Market Cap to Net Income Entera Bio Ltd. ENTX|HYFT: PEG Multiple|ABVC BioPharma, Inc (ABVC) - PEG Multiple|Price/Earnings to Growth Multiple CPIX|QNTM: Growth-Adjusted Payback Ratio|PEG Multiple FGEN|Price/Earnings to Growth Multiple Telomir Pharmaceuticals Inc TELO|Price/Earnings to Growth Ratio Rani Therapeutics Holdings, Inc. RANI|Synergy CHC Corp. (SNYR) - Price to Earnings Adjusted for Growth Rate|RLYB - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio LEXX (Lexaria Bioscience)|Pulmatrix (PULM) - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio PTHL (Pheton Holdings)|Price/Earnings to Growth Ratio Aptorum Group Ltd|Price to Earnings Adjusted for Growth Rate Lyra Therapeutics Inc LYRA|Price/Earnings to Growth Ratio Impact BioMedical Inc (IBO)|TNFA (tnfpharma.com) - Growth-Adjusted Payback Ratio|PEG Multiple YCBD (cbdMD)|PEG Multiple PainReform Ltd PRFX|CYTO: Price/Earnings to Growth Multiple|Lipella Pharma - Company Value to Earnings Growth Ratio|OPTN: PEG Multiple|PIRS - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Procaps|Price to Earnings Adjusted for Growth Rate Petros Pharmaceuticals Inc PTPI|Price/Earnings to Growth Ratio Qilian International Holding Group Limited (QLI)|ACELYRIN Inc. - Growth-Adjusted P/E Ratio|Price/Earnings to Growth Ratio TFF Pharmaceuticals TFFP